A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

Inclusion Criteria: * Non smokers or light smokers and willing to limit smoking for the period of confinement to 4 cigarettes per day * Body Mass Index of 18-35 kg/m2 * Negative test for breathalyzer alcohol and drugs of abuse and HIV antibody test at Screening * Agrees to protocol-defined use of effective contraception * Participants with Mild or Moderate Hepatic Impairment * Must have mild or moderate hepatic impairment * On a stable dose of medication and/or treatment regimen for at least 2 weeks before dosing as well as during the study * Clinical laboratory evaluations within the reference range for the test laboratory * Participants with normal hepatic function have no clinically significant findings from medical history, physical examination, Laboratory values within protocol defined parameters Exclusion Criteria: * Any other investigational study drug trial within 5 half-lives of that investigational study drug or 30 days prior to dosing with Abiraterone acetate, whichever is longer * Inability to swallow four (4) 250 mg abiraterone acetate tablets * History of or current clinically significant medical illness that would potentially alter absorption and/or excretion of orally administered drugs * History or presence of a clinically significant abnormal ECG * Donation of blood or significant loss of blood within 56 days prior to Day 1 or planned donation of blood or plasma from Screening through 30 days after Day 1 * Use of any prescription medications/products or any OTC, non-prescription unrelated to existing allowable stable medical conditions within 5 half-lives of that product or 7 days prior to dosing with abiraterone acetate, whichever is longer * Clinically significant renal laboratory findings * Participants with Mild or Moderate Hepatic Impairment will be excluded - any significant medical history other than hepatic impairment that may affect the interpretation of the data or which otherwise contraindicates participation in the study * Acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function as indicated by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment within 2 weeks * Autoimmune liver disease; Esophageal variceal bleeding within 6 months prior to Screening, unless successfully treated with banding, Gastric varices * Spontaneous bacterial peritonitis within 3 months prior to Screening * Portosystemic shunt, Organ transplant, Wilson's disease, Cholestatic liver disease (e g , primary biliary cirrhosis or primary sclerosing cholangitis) * Clinically significant laboratory findings except as related to hepatic impairment * Control Participants with Normal Hepatic Function Any significant laboratory results, including specifically Positive for Hepatitis B or C, Hemoglobin \< 12 0 g/dL LFTs outside of normal limits